TuHURA Biosciences, Inc./NV financial data

Symbol
HURA on Nasdaq
Location
10500 University Center Dr., Suite 110, Tampa, FL
State of incorporation
NV
Fiscal year end
December 31
Former names
Kintara Therapeutics, Inc. (to 10/22/2024), DelMar Pharmaceuticals, Inc. (to 8/18/2020), Berry Only Inc. (to 1/18/2013)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 219 % +41.9%
Debt-to-equity 75.5 % -47.3%
Return On Equity -268 % +53.2%
Return On Assets -153 % +35.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.75M shares -97.8%
Entity Public Float 1.72B USD +14886%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.59M shares +3137%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.06M USD -86.8%
General and Administrative Expense 6.64M USD +29.9%
Nonoperating Income (Expense) 179K USD +84.5%
Net Income (Loss) Attributable to Parent -7.52M USD +42.2%
Earnings Per Share, Basic 62.2 USD/shares +97.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.02M USD +1298%
Assets, Current 3.48M USD +345%
Property, Plant and Equipment, Net 657K USD -5.33%
Assets 4.14M USD +180%
Accounts Payable, Current 1.87M USD
Accrued Liabilities, Current 336K USD
Liabilities, Current 2.26M USD -32.3%
Liabilities 2.45M USD -30.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 21K USD 0%
Retained Earnings (Accumulated Deficit) -162M USD -4.88%
Stockholders' Equity Attributable to Parent 1.7M USD
Liabilities and Equity 4.14M USD +180%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.89M USD -43.4%
Net Cash Provided by (Used in) Financing Activities -2M USD -205%
Net Cash Provided by (Used in) Investing Activities -232K USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 1.59M shares -8.94%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.89M USD -43.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.02M USD +1298%
Deferred Tax Assets, Valuation Allowance 31.3M USD -3.16%
Deferred Tax Assets, Gross 31.3M USD -3.16%
Depreciation 17K USD +13.3%
Payments to Acquire Property, Plant, and Equipment 859K USD
Deferred Tax Assets, Operating Loss Carryforwards 27.9M USD -4.43%
Preferred Stock, Shares Authorized 5M shares 0%
Share-based Payment Arrangement, Expense 545K USD -51.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%